Arcutis Biotherapeutics surges on strong Q3 results, Zoryve growth, and a bullish FY 2026 outlook. Click here to find out why ...

Hepatocellular carcinoma (HCC) is the sixth leading cause of cancer-related mortality worldwide.1 Despite therapeutic ...

InnoCare begins patient dosing in global phase II trial of TYK2 inhibitor, Soficitinib to treat prurigonodularis: Beijing Monday, December 1, 2025, 12:00 Hrs [IST] InnoCarePharma, ...

US drugmaker AbbVie has announced two updates for Canadians living with ulcerative colitis (UC) in relation to its drug ...

India’s economy grew at a robust 8.2 pc in second quarter (July–Sept) of the current financial year, up from 5.6 per cent in the same quarter ...

InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today ...

According to research by SNS Insider, the U.S. Atopic Dermatitis Drugs Market is projected to grow at a CAGR of 8.57%, supported by high disease burden, strong R&D pipelines, and rapid adoption of ...

Soficitinib is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related autoimmune disorders. The Current indications under development are ...

The use of IL-1 alpha and beta inhibition with ARCALYST has increasingly become the preferred treatment for recurrent ...

Intel has responded to TSMC, alleging that a former semiconductor staffer leaked trade secrets and confidential information ...

The huge fire that ripped through a former nightclub in Wigan is being investigated as possible arson, say police. Emergency ...

Background Valproate exposure during pregnancy causes major congenital malformations in 11% and neurodevelopmental disorders in 30–40% of exposed children. Despite regulatory interventions, including ...